NIAID-supported investigators are conducting a wide range of research on all areas of HIV/AIDS, including developing and testing preventive HIV vaccines, prevention strategies, and new treatments for HIV and associated coinfections, co-morbidities, and complications. Through laboratories and clinics on the NIH campus in Bethesda, MD, and a vast network of research supported at universities, medical centers, and clinical trial sites around the globe, NIAID is working to better understand HIV and how it causes disease, find new tools to prevent HIV infection including a preventive vaccine, develop new and more effective treatments for people living with HIV, and hopefully, find a cure.
Through the information offered here, researchers can learn about the science being conducted at NIAID and by NIAID-funded researchers. Researchers seeking funding can access opportunities to further their own research, while NIAID and NIH grantees can find out about available resources outside of specific funding opportunities. Recent publications, active networks, and ways to connect with other researchers are also available.
NIAID contracts support the development of emerging HIV therapeutics, vaccines, and non-vaccine biomedical prevention (nBP) candidates.
Martin Delaney Collaboratories for HIV Cure Research, the flagship NIH program on HIV cure research, will host the sixth biennial Strategies for an HIV Cure meeting on October 12-13, 2023.
Programs & Networks
NIAID encourages partnerships among other agencies and foundations, private industry, federal and local government and other organizations with similar goals to help build and sustain research infrastructure and to translate and implement research findings as public health practices.
Such partnerships ensure that the research will lead to findings that are ultimately feasible and meaningful for impacted communities. NIAID is deeply committed to local and international research collaboration that are mutually beneficial and scientifically productive.
Related NIH Programs
For decades NIAID had supported the separate Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS) cohort studies. MACS was a study of gay and bisexual men, while WIHS was a study of women who had other risk factors for HIV.
In 2019, the National Heart, Lung, and Blood Institute (NHLBI) became the primary steward of the new MACS/WIHS-CSS. For this effort, the NHLBI is working in close collaboration with the NIH Office of AIDS Research (OAR) as well as several co-funding institutes across the NIH.